Also known as: mAbs
Engineered extracellular vesicles deliver IL-2 and therapeutic antibodies with precision, reducing systemic toxicity and targeting inflamed tissues in autoimmune disease, cancer, and inflammatory bowel disease. Microfluidic electroporation enables efficient IL-2 loading, while exosome nanovesicles show efficacy in preclinical colitis models.
Two new studies clarify how Epstein-Barr virus may trigger multiple sclerosis: one shows a doubled CD4+ T cell response in untreated patients, while another reveals EBV-activated B cells cause brain inflammation in mice. Insights point to potential therapies targeting EBV-specific immune activity.
WHO has launched the PARTNERS clinical trial testing MBP134 and remdesivir for Bundibugyo virus disease in the DRC. Advisers recommend limiting all candidate Ebola drugs to clinical trials. The outbreak has caused 1,792 confirmed cases and 625 deaths as of July 9.
A new antibody-drug conjugate targeting IL1RAP has shown potent preclinical activity against Ewing sarcoma and other fusion-driven cancers, with minimal off-target toxicity. Researchers at UBC report tumor eradication and reduced metastasis, with clinical trials being planned.
Scientists have identified SLAMF6 as a key suppressor of T cell immunity against cancer and developed monoclonal antibodies that neutralize it in mice, published in Nature. Biotechnology company Replimune Group has reported its 2026 financial position, with a market value of approximately $234.5 million and ongoing clinical trials.
The Gyrolab automated immunoassay platform from Gyros Protein Technologies addresses reproducibility and throughput challenges in biotherapeutic development for ADCs and bispecifics. Case studies show measurable improvements in assay consistency and efficiency for titer and impurity testing workflows.
Bharat Biotech, Naprod Life Sciences, and Hetero Biopharma are hiring for production, R&D, and microbiology roles. Openings require B.Sc/M.Sc/B.Tech with 0–12 years of experience.
HKUST researchers developed LPAT, a glycan-targeting therapy that prevents breast cancer metastasis in mouse models. It completely inhibited metastatic lung tumor onset. Findings published in Biomaterials.
Global virus filters markets are projected for strong growth through 2035, with CAGRs of 7.2% to 8.2%, driven by expanding biologics production and stringent regulatory mandates for viral safety. Monoclonal antibody manufacturing remains the largest segment, while advanced therapy medicinal products are the fastest-growing area of demand.
Recent market reports forecast significant growth in the progressive pulmonary fibrosis market, set to reach $2.7 billion by 2035, and the global asthma and COPD drugs market, projected to hit US$ 82.2 billion by 2036. The Asia Pacific pharma 4.0 market is also expanding rapidly, driven by digital technologies like AI and IoT.
